Leveraging oncology gene expression signatures to accelerate research

Immuno-Oncology Insights 2022; 3(7), 357

DOI: 10.18609/ioi.2022.037

Published: 2 July 2022
Sarah Church

RNA signatures are at the forefront of cancer research and can enhance study outcomes and accelerate the translation of findings from the bench to the clinic.

In this video and poster from Immuno-oncology Insights, Sarah Church discusses a gene expression panel containing 770 human genes in total, profiling the tumor, microenvironment, and immune response. It contains 48 biological signatures, including the Tumor Inflammation Signature (TIS) which measures activity known to be associated with response to PD-1/PD-L1 blockade therapy.

Watch the video, read the scientific poster, or submit your own question to the presenter for insights into:

  • Panels with clinically, analytically, and biologically established signatures which can be used to vastly improve the statistical power and interpretation of data
  • Research signatures focusing on biological themes including tumor immunogenicity, inhibitory tumor mechanisms, anti-tumor immune activity, stromal factors, inhibitory immune signaling, and immune cell population abundance
  • The framework and processes that went into developing the signatures

Sarah Church focuses on developing and applying NanoString platforms to address key research areas in immunology and oncology. As part of that mission, Sarah works with academics, biopharmas, and clinicians to identify unmet needs in translational research and create novel products for transcriptional and proteomic profiling. Sarah oversees strategic collaborations to help investigators utilize NanoString tools in their research with the goal of developing new biomarkers that can be deployed as clinical diagnostics. Sarah also leads our data analysis service team to support customers to get the most out of their NanoString data. Prior to joining NanoString, Sarah worked on developing immune-based predictive and prognostic biomarkers for solid tumors at INSERM in Paris, France. Sarah has a PhD in molecular microbiology and immunology from Oregon Heath and Sciences University and BA in biology from Scripps College.